On Demand Webinars
Late-phase biologics development: Embracing risk for competitive advantage
Risk is omnipresent in biologics development, particularly in late-phase manufacturing. Fears of a therapeutic candidate not meeting efficacy goals despite early positive results, alongside safety, quality, and scale-up concerns, loom large.
Innovative AI-Driven Solutions to Address the Growing Complexity of APIs
The complexity of small molecule active pharmaceutical ingredients (APIs) is rising, bringing longer syntheses that challenge innovators' timely readiness for the Clinic.
Utilizing Live Cell Imaging for Better Lead Selection of Biologics and Bioconjugates
Abzena is a Contract Design and Manufacturing Organisation (CDMO) focused on the development of complex biologics, including antibody-drug conjugates (ADCs) and bispecific antibodies.
Breaking Boundaries in Targeted Protein Degradation
Targeted protein degradation is redefining what’s possible in modern drug discovery. By harnessing the cell’s own machinery to eliminate disease-causing proteins, degraders and molecular glues are moving science beyond traditional inhibition—and into a new era of precision and control.
Modern Requirements for Laboratory Balances: A Global Pharmacopoeial Perspective
In recent years, the regulatory requirements for balances used in pharmaceutical analysis have undergone significant updates across major pharmacopoeias — including the USP (United States Pharmacopeia, latest version 07/2025), Ph. Eur. (European Pharmacopoeia, 07/2021, currently under revision), JP (Japanese Pharmacopoeia, 06/2024), and ChP (Chinese Pharmacopoeia, 03/2025).
Accelerate with Confidence: Research-Based Insights to guide CDMO-CRO Partnership Decisions
In drug development, every delay has a price—lost time, lost opportunity, and lost market share. Escalating costs, complex modalities, strict regulations, and supply chain challenges are making speed and precision more critical than ever.
Al and Multimodal Research: Turning Biological Complexity into Therapeutic Opportunity
Drug discovery is increasingly multimodal, spanning small molecules, antibodies, RNA-based therapies, cell and gene therapies, and novel combinations like ADCs.
Overcoming AAV manufacturing bottlenecks: A scalable approach with stable producer cell lines
As gene therapy moves beyond rare diseases, the gene therapy field faces a common challenge: how to scale AAV manufacturing efficiently.
Particle Risk Mitigation in Biomanufacturing
Join Entegris for an expert-led webinar exploring how particle contamination impacts biopharmaceutical manufacturing—and what you can do to detect, prevent, and remove it effectively.
Best practice Laboratory 4.0 – Weighing meets Titration
In an On Demand Webinar, Natali Hürlemann, Jr. Product Manager Software at Metrohm International Headquarters, and Lucas Foerster, Product Manager Lab Weighing at Sartorius, present a best practice example.
